Global pulmonary embolism therapeutics market to post 9% CAGR over next five years

May 20, 2019 Off By BusinessWire

LONDON–(BUSINESS WIRE)–The global pulmonary embolism therapeutics market is expected to post a
CAGR of more than 9% during the period 2019-2023, according to the
latest market research report by Technavio.

A key factor driving the growth of the global pulmonary embolism
therapeutics market is the growing risk factors associated with
pulmonary embolism. Several lifestyle-related factors such as
overweight, old-age pregnancy, smoking, and excessive use of
supplemental estrogen are some of the major cause of pulmonary embolism
globally. The decrease in mobility due to overweight can cause blood to
clot throughout the body, resulting in the difficulty in breathing that
further increases the risk of a clot in the lungs. Obese people with
high blood pressure are also prone to be affected with the pulmonary
embolism. Further, the use of supplemental estrogen or hormone
replacement therapy can also cause blood clots in the lungs. Thus, the
increase in the risk factors associated with pulmonary embolism will
drive market growth during the forecast period.

As per Technavio, the extensive research on regenerative therapies will
have a positive impact on the market and contribute to its growth
significantly over the forecast period. This global
pulmonary embolism therapeutics market 2019-2023
research report also analyzes other important trends and
market drivers that will affect market growth over 2019-2023.

Global pulmonary embolism therapeutics market:
Extensive research on regenerative therapies

Although the market has the highly effective new-age oral anticoagulants
for the treatment of pulmonary embolism, it is still witnessing a huge
unmet need considering the pathogenesis of the disease. The treatment
options that are currently available in the market are symptomatic,
which requires the patients to undergo treatment for long durations. As
a result, researchers are constantly studying various proteins and genes
that are known to cause pulmonary embolism. Thus, the advances in the
research are will bring in a paradigm shift in the treatment landscape
for pulmonary embolism over the years to come.

“With the aim to enhance the research and the development of novel
drugs for the treatment of pulmonary embolism, various vendors are
venturing into strategic alliances which are helping them in
concentrating on their core competencies such as research. These
increasing strategic alliances are also expected to result in decreasing
the competition among the vendors and increase their global presence
during the forecast period,” says a senior research analyst at
Technavio.

Global pulmonary embolism therapeutics market:
Segmentation analysis

This market research report segments the global pulmonary embolism
therapeutics market by RoA (oral and parenteral) and geographic regions
(North America, Europe, Asia, and ROW).

The North American region led the market in 2018, followed by Europe,
Asia, and ROW respectively. The market growth in North America can be
attributed to the increasing prevalence of the indication in the region
with the US being one of the highest prevalent countries of pulmonary
embolism globally. Factors such as the increasing obese population and
the strong prevalence of HIV are expected to further increase the risk
of pulmonary embolism in the region.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

- Market ecosystem

- Market characteristics

- Market segmentation analysis

Market Sizing

- Market definition

- Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

- Regional comparison

- Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

- Vendors covered

- Vendor classification

- Market positioning of vendors

- Competitive scenario

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at [email protected].